The pharmaceutical sector has been impacted by COVID-19 in several ways. Production of active pharmaceutical ingredients has slowed down due to lockdowns in major producing countries like China and India, resulting in higher costs and less availability of materials. Digital health solutions are gaining popularity as people turn to telemedicine and health apps during the pandemic. The supply and distribution of medicines and medical supplies has also been disrupted. Certain drugs, especially generics, have faced shortages as supply was managed through existing inventory for the first two months of disruptions.